BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Boston Scientific (BSX) Announces Acquisition Of Precision Vascular Systems, Inc.


10/19/2005 5:10:44 PM

NATICK, Mass., April 7 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today announced that it has acquired Precision Vascular Systems, Inc. (Precision Vascular), a privately held company located in West Valley City, Utah. Boston Scientific exercised an exclusive option to acquire Precision Vascular that it obtained as part of a series of agreements between Boston Scientific and Precision Vascular in 2002. Terms of the acquisition were not disclosed.

Precision Vascular designs, develops and manufactures high performance medical devices for use in accessing the brain, the heart and other areas of the anatomy. Its primary focus has been the development of a proprietary line of guidewires and microcatheters using a microfabrication manufacturing process that cuts minute slices in small-diameter nitinol tubes. These tubes are designed to improve performance characteristics of guidewires and catheters, making it easier for physicians to access complex parts of the anatomy. Precision Vascular was founded with intellectual property and technology originally developed by Sarcos, Inc. Sarcos, Inc. is a research and development company specializing in medical devices, microsystems and robotics.

Precision Vascular's current portfolio of approved devices is used primarily for accessing brain aneurysms, tumors and other blood vessel lesions of the brain. Boston Scientific has identified potential applications of the Precision Vascular technology to projects in its interventional cardiology, oncology and endoscopy businesses, including a new interventional cardiology guidewire platform currently under development.

The total worldwide market for vascular access devices, including interventional guidewires and microcatheters, is estimated to be greater than $500 million annually. Demand for high performance access devices is expected to continue to grow with the increasing complexity and number of endovascular and endoscopic procedures being performed.

"We are pleased to welcome the Precision Vascular team to the Boston Scientific family," said Paul LaViolette, Boston Scientific Senior Vice President and Group President, Cardiovascular. "Their 10 years of experience in microfabrication development and manufacturing will prove valuable as we explore future high performance Boston Scientific catheter products to help clinicians access complex target sites."

"The acquisition of Precision Vascular by Boston Scientific represents the culmination of a strong working relationship developed by the companies during the 18 months since we established our distribution agreement and began collaborating on product development," said Ken Osborn, President of Precision Vascular. "I am looking forward to continuing our work together as part of the same company."

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.

CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation

Boston Scientific Corporation

CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569, or PaulDonovan, Media Relations, +1-508-650-8541, both of Boston ScientificCorporation



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES